resTORbio Announces Additional RTB101 Phase 2b Data

resTORbio (Nasdaq:TORC) today announced additional positive results from its dose-ranging Phase 2b clinical trial of RTB101, an oral, selective and potent inhibitor of target of rapamycin complex 1 (TORC1), in respiratory tract infections (RTIs), as well as results from pre-specified analyses for any infection and urinary tract infections (UTIs).

As quoted in the press release:

Analysis of secondary and exploratory endpoints expands upon positive topline results announced in July 2018, which demonstrated a statistically significant 30.6% reduction in the percentage of patients with laboratory-confirmed RTIs during the 16-week treatment period in the RTB101 10 mg once daily dosing cohort compared to the placebo cohort (p=0.025).

“RTB101 10 mg once daily was observed to decrease not only the incidence of RTIs, but also the severity of RTI symptoms. We look forward to advancing this dose in a planned Phase 3 program for reducing the incidence of RTIs in high-risk elderly patients,” said Joan Mannick, M.D., Co-Founder and Chief Medical Officer of resTORbio. “These data also demonstrate that RTB101 may decrease the incidence of other infections in the elderly, including UTIs. It remains to be determined if the most efficacious RTB101 dose for preventing RTIs and UTIs differs because UTIs occur in a different organ system and are caused by different pathogens than RTIs. We continue to develop our clinical strategy for UTIs, including dose selection.”

Click here to read the full press release.